A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 136 participants.

Also called NCT06142383

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 136 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06142383
Other papers using this trial's data
  • The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial Nature medicine, 2026-05 DOI, PubMed 41912806, PMC13190253 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, China, Germany, Hungary, India, Italy, Japan, Portugal, Slovakia, Spain, Taiwan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT06142383. Randomized; double masking; primary purpose treatment. Start 2023-12-12 (actual); primary completion 2024-11-01 (actual). Results posted on 2025-12-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
Condition
Heart Failure
Intervention (Biological)
Placebo
Intervention (Biological)
XXB750 Low dose
Intervention (Biological)
XXB750 Medium Dose
Intervention (Biological)
XXB750 High Dose
Intervention (Drug)
Sacubitril/valsartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06142383
Content hash
24603f8fa71ad905c652ca5ee7e370961736f06c7bc61b3efd1769060c9c582d